Artemisinin: An alternative treatment for oral squamous cell carcinoma

Anticancer Research

Volumn 24, Issue 4, 2004, Pages 2153-2160

  Yamachika, Eiki ^a,b   Habte, Temesgen ^a   Oda, Dolphine ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Artemisinin; Oral squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; ARTEMISIN; ARTESUNATE; CD40 ANTIGEN; CD40 LIGAND; CISPLATIN; FLUOROURACIL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

AGED; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CELL CYCLE; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; EPITHELIUM CELL; FLOW CYTOMETRY; GINGIVA; HAIR LOSS; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LARYNX CANCER; MALE; MOUTH CARCINOMA; NAUSEA; NICK END LABELING; NONHUMAN; PANCYTOPENIA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANTIGENS, CD40; ANTINEOPLASTIC AGENTS; ARTEMISININS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, SQUAMOUS CELL; CD40 LIGAND; CELL CYCLE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MOUTH NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SESQUITERPENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 4444240287     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Klayman DL: Qinghaosu (artemisinin): an antimalarial drug from China. Science 228: 1049-1055, 1985.
2. Woerdengab HJ, Moskal TA, Pras N, Malingre Th M, Elferaly FS, Kampinga HH and Konings AWT: Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumour cells. J Nat Prod 56: 849-856, 1993.
3. Lai H and Singh NP: Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett 91: 41-46, 1995.
4. Singh NP and Lai H: Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci 70: 49-56, 2001.
5. Galal AM, Ross SA, ElSohly MA, ElSohly HN, El-Feraly FS, Ahmed MS and McPhail AT: Deoxyartemisinin derivatives from photooxygenation of anhydrodeoxydihydroartemisinin and their cytotoxic evaluation. J Nat Prod 65: 184-188, 2002.
6. Syrjanen SM, Syrjanen KJ and Happonen RP: Human papillomavirus (HPV) DNA sequences in oral precancerous lesions and squamous cell carcinoma demonstrated by in situ hybridization. J Oral Pathol 17: 273-278, 1988.
7. Kiyabu MT, Shibata D, Arnheim N, Martin WJ and Fitzgibbons PL: Detection of human papillomavirus in formalin-fixed, invasive squamous carcinomas using the polymerase chain reaction. Am J Surg Pathol 13: 221-224, 1989.
8. Oda D, Bigler L, Lee P and Blanton R: HPV immortalization of human oral epithelial cells: a model for carcinogenesis. Exp Cell Res 226: 164-169, 1996.
9. Oda D, Bigler L and Disteche C: Chromosomal abnormalities in HPV 16-immortalized human oral epithelial cells. Carcinogenesis 17: 2003-2008, 1996.
10. Merlano M, Benasso M, Cavallari M, Blengio F and Rosso M: Chemotherapy in head and neck cancer. Eur J Cancer B Oral Oncol 30B: 283-289, 1994.
11. Perry MC editor: The Chemotherapy Source Book. 2nd ed. Baltimore, Williams and Wilkins, 1996, pp 318-325.
12. Hien TT and White NJ: Qinghaosu. Lancet 341: 603-608, 1983.
13. Taylor WR and White NJ: Antimalarial drug toxicity: a review. Drug Saf 27(1): 25-61, 2004.
14. Tong D, Poot M, Hu D and Oda D: 5-Fluorouracil-induced apoptosis in cultured oral cancer cells. Oral Oncol 36: 236-241, 2000.
15. Rabinovitch P: DNA content histogram and cell cycle analysis. Methods Cell Biol 41: 127-130, 1994.
16. Parkin DM, Pisani P and Ferlay J: Estimates of the worldwide incidence of 18 major cancers in 1985. Int J Cancer 54: 594-606, 1993.
17. McAndrew PG: Oral cancer and precancer: treatment. Br Dent J 168: 191-198, 1990.
18. Posner MR and Colevas AD: Induction chemotherapy in the management of squamous cell cancer of the head and neck. Cancer J Scient Amer 3: 73-75, 1997.
19. MacConald JS ed: Manual of Oncologic Therapeutics. 3rd ed. Philadelphia, JB Lippincott, 1991, pp111-113.
20. Merlano M, Benasso M, Cavallari M, Blengio F and Rosso M: Chemotherapy in head and neck cancer. Eur J Cancer B Oral Oncol 30B: 283-289, 1994.
21. Singh NP and Verma KB: Case report of a laryngeal squamous cell carcinoma treated with artesunate. Arch Oncol 10(4): 279-280, 2002.
22. Jeyadevan JP, Bray PG, Chadwick J, Mercer AE, Byrne A, Ward SA, Park BK, Williams DP, Cosstick R, Davies J, Higson AP, Irving E, Posner GH and O'Neill PM: Antimalarial and antitumor evaluation of novel C-10 non-acetal dimers of 10beta-(2-Hydroxyethyl)deoxoartemisinin. J Med Chem 47(5): 1290-1298, 2004.
23. Chen HH, Zhou HJ and Fang X: Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol Res 48(3): 231-236, 2003.
24. Moore JC, Lai H, Li JR, Ren RL, McDougall JA, Singh NP and Chou CK: Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. Cancer Lett 98(1): 83-87, 1995.
25. Iwata E, Asanuma M, Nishibayashi S, Kondo Y and Ogawa N: Different effects of oxidative stress on activation of transcription factors in primary cultured rat neuronal and glial cells. Brain Res Mol Brain Res 50: 213-220, 1997.
26. Pastrorino JG, Chen ST, Tafani M, Synder JW and Faber JL: The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition. J Biol Chem 273: 7770-7775, 1998.
27. Levine AJ: p53 the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
28. Crochemore C, Michaelidis TM, Fisher D, Loeffler JP and Almedia OF: Enhancement of p53 activity and inhibition of neural cell proliferation by glucocorticoid receptor activation. FASEB J 16: 761-770, 2002.
29. Chen X, Ko LJ, Jayaraman L and Prives C: p53 levels, functional domains and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 10: 2438-2451, 1996.
30. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van Kooten C, Liu YJ, Rousset F and Saeland S: The CD40 antigen and its ligand. Annu Rev Immunol 12: 881-922, 1994.
31. Eliopoulos AG, Dawson CW, Mosialos G, Floettmann JE, Rowe M, Armitage RJ, Dawson J, Zapata JM, Kerr DJ, Wakelam MJ, Reed JC, Kieff E and Young LS: CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 13: 2243-2254, 1996.
32. Spriggs MK, Armitage RJ, Strockbine L, Clifford KN, Macduff BM, Sato TA, Maliszewski CR and Fanslow WC: Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. J Exp Med 176: 1543-1550, 1992.
33. Armitage RJ, Fanslow WC, Strockbine L, Sato TA, Clifford KN, Macduff BM, Anderson DM, Gimpel SD, Davis-Smith T and Maliszewski CR: Molecular and biological characterization of a murine ligand for CD40. Nature 357: 80-82, 1992.